Diversifying Investments: A Portfolio Manager's Strategic Shift to Healthcare and Robotics ETFs

Strategic Portfolio Adjustments for Future Growth

Introducing New ETFs: Healthcare and Robotics

Chris Versace, the portfolio manager behind TheStreet Pro Portfolio, has recently made significant additions to his investment lineup. On August 5, he initiated positions in two distinct ETFs: the Health Care Select Sector SPDR ETF (XLV) and the Robo Global Robotics and Automation Index ETF (ROBO). This decision marks a deliberate move to expand the portfolio's exposure beyond its existing cybersecurity focus, tapping into new markets that Versace anticipates will demonstrate sustained growth over the coming years.

Investment Sizing and Prudent Allocation

The Pro Portfolio acquired 395 shares of XLV at approximately $164 per share, representing about 1% of the total portfolio assets. Additionally, 575 shares of ROBO were purchased at around $84.50 each, accounting for approximately 0.75% of assets. Both new positions received an initial rating of 'Two', reflecting a cautious stance given the market's recent robust performance. Versace intends to gradually build these positions over time, leveraging market pullbacks to acquire additional shares rather than deploying capital all at once. This measured strategy mirrors his previous successful approach with the First Trust Nasdaq Cybersecurity ETF (CIBR).

Establishing Price Targets and Review Checkpoints

Initial price targets have been set at $180 for XLV and $95 for ROBO, indicating potential upsides of roughly 10% and 12% respectively from the entry prices. Crucially, the portfolio has also established checkpoint levels: $144 for XLV and $70 for ROBO. Should either ETF reach these thresholds, a comprehensive review will be triggered, allowing Versace to re-evaluate the investment thesis. This mechanism provides a safeguard, ensuring that the portfolio remains agile and responsive to changing market conditions.

Rationale Behind the Healthcare Sector Investment (XLV)

The XLV ETF tracks the Health Care Select Sector Index, encompassing a broad spectrum of the healthcare industry, including pharmaceuticals, biotechnology, medical devices, healthcare providers, and life sciences. Managing over $41 billion in assets across 63 companies, its top holdings feature industry giants like Eli Lilly, Johnson & Johnson, AbbVie, Merck, and Amgen. State Street's recent upgrade of the healthcare sector from neutral to positive in its Q3 2026 outlook further underscores the improving conditions within this market. Versace chose an ETF to gain broad exposure, mitigating risks associated with individual stock performance. The long-term case for healthcare is compelling, driven by an aging U.S. population and the consistent demand for healthcare services, especially given that the sector has lagged behind large-cap technology in recent years.

The Strategic Imperative for Robotics and Automation (ROBO)

The ROBO ETF focuses on companies involved in robotics, automation, artificial intelligence applications, and the foundational industrial technologies supporting these fields. Versace views the robotics market as an increasingly indispensable opportunity, observing growing automation investments across diverse industries. ROBO Global reports that this ETF has delivered an annualized return of 8.64% since its inception in January 2014. The application of robotics extends far beyond traditional manufacturing, now playing a crucial role in logistics, healthcare, defense, and agriculture, addressing labor shortages and cost-cutting pressures. Furthermore, recent depreciation provisions, such as those from the 'One Big Beautiful Bill', incentivize companies to invest in automation, providing a near-term boost. The robotics investment also aligns with existing portfolio themes, as the growth in this sector will drive demand for computing and networking, complementing the portfolio's focus on autonomous vehicles. However, given its sensitivity to valuation and capital spending cycles, the initial ROBO position is smaller, reflecting a more cautious stance on its inherent market volatility.

Factors Influencing Future Performance and Adjustments

Versace plans to continually reassess price targets for both ETFs as Wall Street analysts update their forecasts during earnings seasons. Strong quarterly results from key XLV holdings, such as Eli Lilly or AbbVie, could lead to higher targets for the healthcare ETF. Similarly, improved capital spending data or enhanced clarity on automation policies could bolster ROBO's target. Both positions could also benefit from a rotation of funds out of technology stocks and into healthcare and industrial sectors. A decline in interest rates would particularly favor ROBO, as lower borrowing costs tend to uplift valuations for growth-oriented assets. The established checkpoint levels for XLV ($144) and ROBO ($70) serve as critical junctures for review. Should these levels be reached, Versace will evaluate whether the original investment rationale remains valid. A continued strong thesis might prompt further investment at lower prices, while a weakened outlook could lead to exiting the position. These are long-term investments, not short-term trades, with initial allocations carefully calibrated to allow for adjustments and mitigate potential downsides.